Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 190
- Registration Number
- NCT00154193
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Phase 2
Completed
- Conditions
- Life Threatening Diseases
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT00154388
Efficacy and Safety of Imatinib in Chordoma
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT00150072
- Locations
- 🇨🇭
Novartis Investigative Site, Lausanne, Switzerland
Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients
Phase 3
Completed
- Conditions
- Heart Transplantation
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 176
- Registration Number
- NCT00150046
- Locations
- 🇨🇭
Basel Novartis Pharma AG, Basel, Switzerland
🇩🇪Novartis Investigational Site, Germany, Germany
Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients
Phase 3
Completed
- Conditions
- Renal Transplant
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00149903
- Locations
- 🇨🇳
General Hospital, Friendship Hospital, Beijing, No 1 Hospital Peking University, Beijing China; Shanghai No 1 Hospital, Shanghai China; Changzheng Hospital, Shanghai, China; Shanghai Ruij, Beijing, China
Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 139
- Registration Number
- NCT00149916
Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients
Phase 4
Completed
- Conditions
- Liver Transplant
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT00149994
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
- Conditions
- Organ Transplantation
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00149981
- Locations
- 🇬🇧
Novartis Investigative Site, Salford, United Kingdom
Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)
Phase 4
Completed
- Conditions
- Kidney Maintenance Transplant
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 335
- Registration Number
- NCT00150007
Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1869
- Registration Number
- NCT00142298
- Locations
- 🇬🇧
Novartis Investigational Site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath